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Abstract
Background: The mechanism of leukocyte transendothelial migration (TEM) across the highly restrictive blood-brain
barrier (BBB) remains enigmatic, with paracellular TEM thought to require leukocytes to somehow navigate the
obstructive endothelial tight junctions (TJs). Transient interactions between TJ proteins on the respective leukocyte and
endothelial surfaces have been proposed as one mechanism for TEM. Given the expanding role of extracellular vesicles
(EVs) in intercellular communication, we investigated whether EVs derived from brain microvascular endothelial cells
(BMEC) of the BBB may play a role in transferring a major TJ protein, claudin-5 (CLN-5), to leukocytes as a possible basis
for such a mechanism during neuroinflammation.
Methods: High-resolution 3D confocal imaging was used to highlight CLN-5 immunoreactivity in the central
nervous system (CNS) and on leukocytes of mice with the neuroinflammatory condition experimental
autoimmune encephalomyelitis (EAE). Both Western blotting of circulating leukocytes from wild-type mice and
fluorescence imaging of leukocyte-associated eGFP-CLN-5 in the blood and CNS of endothelial-targeted, Tie-2-
eGFP-CLN-5 transgenic mice were used to confirm the presence of CLN-5 protein on these cells. EVs were
isolated from TNF-α-stimulated BMEC cultures and blood plasma of Tie-2-eGFP-CLN-5 mice with EAE and
evaluated for CLN-5 protein by Western blotting and fluorescence-activated cell sorting (FACS), respectively.
Confocal imaging and FACS were used to detect binding of endothelial-derived EVs from these two sources to
leukocytes in vitro. Serial electron microscopy (serial EM) and 3D contour-based surface reconstruction were
employed to view EV-like structures at the leukocyte:BBB interface in situ in inflamed CNS microvessels.
(Continued on next page)
* Correspondence: pachter@uchc.edu
1Blood-Brain Barrier Laboratory, University of Connecticut Health Center, 263
Farmington Ave., Farmington, CT 06070, USA
2Department of Cell Biology, University of Connecticut Health Center, 263
Farmington Ave., Farmington, CT 06070, USA
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Paul et al. Journal of Neuroinflammation  (2016) 13:292 
DOI 10.1186/s12974-016-0755-8
(Continued from previous page)
Results: A subpopulation of leukocytes immunoreactive for CLN-5 on their surface was seen to infiltrate the CNS
of mice with EAE and reside in close apposition to inflamed vessels. Confocal imaging of immunostained samples
and Western blotting established the presence of CLN-5+ leukocytes in blood as well, implying these cells are
present prior to TEM. Moreover, imaging of inflamed CNS vessels and the associated perivascular cell infiltrates
from Tie-2-eGFP-CLN-5 mice with EAE revealed leukocytes bearing the eGFP label, further supporting the hypothesis
CLN-5 is transferred from endothelial cells to circulating leukocytes in vivo. Western blotting of BMEC-derived EVs,
corresponding in size to both exosomes and microvesicles, and FACS analysis of plasma-derived EVs from Tie-2-eGFP-
CLN-5 mice with EAE validated expression of CLN-5 by EVs of endothelial origin. Confocal imaging and FACS further
revealed both PKH-67-labeled EVs from cultured BMECs and eGFP-CLN-5+ EVs from plasma of Tie-2-eGFP-CLN-5 mice
with EAE can bind to leukocytes. Lastly, serial EM and 3D contour-based surface reconstruction revealed a close
association of EV-like structures between the marginating leukocytes and BMECs in situ during EAE.
Conclusions: During neuroinflammation, CLN-5+ leukocytes appear in the CNS, and both CLN-5+ leukocytes and
CLN-5+ EVs are detected in the blood. As endothelial cells transfer CLN-5+ to leukocytes in vivo, and EVs released
from BMEC bind to leukocytes in vitro, EVs may serve as the vehicles to transfer CLN-5 protein at sites of
leukocyte:endothelial contact along the BBB. This action may be a prelude to facilitate TEM through the
formation of temporary TJ protein bridges between these two cell types.
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Background
The blood-brain barrier (BBB) lies at the specialized mi-
crovasculature of the central nervous system (CNS).
Consisting of a unique, continuous endothelium supported
by a composite basement membrane, astrocyte end feet,
and pericytes, its preeminent role is to strictly regulate the
passage of soluble and cellular elements between the circu-
lation and CNS by imposing severe restrictions on solute
transport and cellular migration [1–4]. These restrictions
are thought to be due, in significant part, to the presence
of junctional complexes between endothelial cells [2, 5–7].
Leukocytes can nevertheless cross the BBB in significant
number during neuroinflammation [8–10], though the
mechanism(s) remains vague. One school of thought is
that leukocytes somehow negotiate the series of endothelial
tight junctions (TJs) and adherens junctions (AJs) that nor-
mally restrict the aqueous, inter-endothelial space [11–14].
In fact, a “zipper mechanism” has been proposed sug-
gesting some leukocytes might engage in transendothe-
lial migration (TEM) across particular vascular beds by
temporarily replacing endothelial junctional contacts with
homophilic and/or heterophilic interactions between cor-
responding leukocyte and endothelial junctional/adhesion
proteins [15–18]. But the conventional view has held cir-
culating leukocytes do not express much if any junctional
proteins—at least in the absence of disease [19]—and so
far, there has been no evidence of the zipper mechanism
in the CNS. Even the suggestion that such a mechanism
operates centrally would minimally require confirmation
of CNS leukocytes bearing TJ and/or AJ proteins.
Recent findings, however, support the existence of cir-
culating leukocytes harboring various junctional proteins
and indicate expression of these proteins is related to
neuroinflammation. Specifically, Mandel et al. [20] ob-
served TJ proteins of the claudin (CLN) family—notably
CLN-1 (CLN-1+) and CLN-5 (CLN-5+)—in peripheral
blood leukocytes (PBLs) from both healthy individuals
and those affected with the neuroinflammatory condition
multiple sclerosis (MS). They further noted an increase in
CLN-1 and CLN-5 protein expression by PBLs from MS
patients experiencing disease relapse, compared to healthy
controls or patients in remission. Moreover, effective treat-
ment of relapsing disease with anti-inflammatory glucocor-
ticoids was accompanied by decreased PBL expression of
CLN-5. These findings thus suggest a positive correlation
between leukocyte TJ protein expression and severity of
neuroinflammatory disease. Numerous other studies docu-
menting the presence of many TJ and AJ proteins on vari-
ous leukocyte and other immune cell populations in vitro
and in vivo [21–28] underscore detection of these cells is
not an isolated phenomenon but, instead, a more frequent
occurrence that may be related to immune activation and/
or function.
While ectopic expression of these junctional proteins
by leukocytes may be achieved by endogenous synthesis,
this could also potentially occur by transfer from other
cell types—notably endothelial cells, which are a particu-
larly rich source of TJ and AJ proteins [2, 7, 29]. One
route for such transfer might be via extracellular vesicles
(EVs, previously known as “microparticles”)—nano-size,
membrane-bound structures shed from numerous cells
types—which mediate intercellular communication and
can convey a broad spectrum of bioactive molecules (in-
cluding protein, messenger RNA (mRNA), miRNA, and
DNA) over long and short distances [30–32]. EVs consti-
tute a heterogeneous family of vesicles and are classified
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according to their size and route of derivation. Exosomes
are generally 40–100 nm in diameter and originate from
multivesicular endosome fusion with the plasma mem-
brane, while microvesicles are in the 100–1000-nm range
and arise from exocytic budding of the plasma membrane
[33, 34]. Significantly, EVs can vary in their cargo and
cellular targets [35]. The prospect of EVs acting as vehi-
cles to transfer junctional proteins to leukocytes is par-
ticularly alluring for several reasons. EVs from varied
sources have been reported to contain several junctional
proteins [36–40] and mechanical injury to cultured brain
microvascular endothelial cells (BMEC) found to stimulate
release of EVs harboring the TJ protein occludin [41].
Moreover, several reports reinforce the idea that varied
leukocyte subtypes are physiological targets of endothelial
EVs. In vivo analysis has shown elevated endothelial
EV-leukocyte complexes in plasma from MS patients dur-
ing disease exacerbation [42]. And binding of endothelial
EVs, obtained from blood of patients with severe systemic
inflammatory response syndrome, to neutrophils has been
demonstrated in vitro [43], as has binding of EVs from
BMEC cultures to both monocytes [44] and lymphocytes
[45]. That inflammation in and outside the CNS [46–51],
and adhesion of leukocytes [52], each triggers release of
EVs from endothelial cells supports a juxtacrine mechan-
ism for endothelial EVs to transfer junctional proteins to
leukocytes at or near the BBB during neuroinflammatory
disease.
To address the issues of whether leukocytes bearing TJ
proteins enter the CNS, and the possible origin of these
proteins, initial studies were performed to identify leuko-
cytes harboring the TJ protein CLN-5—a determinant of
the BBB [53]—in the blood and spinal cord of wild-type
mice with experimental autoimmune encephalomyelitis
(EAE), an animal model of MS [54–56]. EAE was then
induced in transgenic mice with eGFP-CLN-5 targeted
to endothelial cells to examine if endothelial cells trans-
fer CLN-5 to leukocytes. To additionally investigate the
potential for EVs to act as vehicles for CLN-5 transfer,
EVs released from cultured BMEC were evaluated for
the presence of CLN-5 and ability to bind to leukocytes.
EVs isolated from the blood of Tie-2-eGFP-CLN-5 trans-
genic mice were similarly evaluated for leukocyte binding
capacity. Finally, serial electron microscopy and 3D
rendering was employed to view possible EVs at the
leukocyte:BBB interface in situ.
Methods
Mice
Wild-type, female C57BL/6 mice, aged 8 to 10 weeks,
were obtained from Charles River Laboratories, Inc.
(Wilmington, MA). Transgenic C57BL/6J mice, expressing
reporter eGFP fused to CLN-5 protein, under direction
of the endothelial Tie-2/Tek-1 promoter/enhancer [57],
referred to from hereon as Tie-2-eGFP-CLN-5 mice,
were obtained from Dr. Dritan Agalliu (Department of
Pathology, Columbia University). All animal experimental
procedures were performed following the Animal Care
and Use Guidelines of the University of Connecticut
Health Center (Animal Welfare Assurance A3471-01)
and approved under protocol 100346-1214.
EAE induction
EAE was induced in mice by active immunization with
MOG35–55 peptide (MEVGWYRSPFSRVVHLYRNGK), of
murine origin (W. M. Keck Biotechnology Resource
Center, Yale University, New Haven, CT) and disease
scored as described [58, 59]. Specific time points of ana-
lysis are referred to as “D” followed by the number of
days after disease induction (e.g., D9 is 9 days after
EAE induction).
Mouse BMEC cultures
BMEC cultures were established from two sources: primary-
derived BMEC or an immortalized cell line. Primary-derived
BMEC were obtained from eGFP-CLN-5 mice by immuno-
bead selection as previously described [60] and maintained
in Dulbecco’s modified Eagle’s medium F-12 (DMEM-F-12)
containing 10% plasma-derived horse serum, 10% fetal
bovine serum, 1% antibiotic-antimycotic (all from Ther-
moFisher Scientific, Grand Island, NY), 100 μg/ml hep-
arin, and 100 μg/ml endothelial cell growth supplement
(BD Biosciences, Bedford, MA), at 37 °C, 5% CO2.
These were used to confirm both the classical junctional
localization of eGFP-CLN-5 (Additional file 1: Figure S1)
and release of eGFP-CLN-5+ EVs (data not shown) from
freshly derived BMEC. It is thus assumed all eGFP sig-
nal associated with endothelial cells, leukocytes, and
EVs stems from eGFP-labeled CLN-5. The immortalized
cell line bEND3, derived from a mouse brain capillary
hemangioma [61] and expressing CLN-5 [62], was ob-
tained from the American Type Culture Collection and
grown in DMEM containing 10% fetal bovine serum and
1% antibiotic-antimycotic, at 37 °C, 5% CO2. These cells
were employed to obtain EVs in bulk for Western blotting
analysis and leukocyte binding.
Isolation of EVs (exosomes and microvesicles) from BMEC
cultures
BMEC were cultured to confluence for all experiments.
Prior to experimentation, cells were switched to media
supplemented with exosome-depleted fetal bovine serum
(Exo-FBS™; Systems Biosciences, Mountainview, CA) and
grown for an additional 12 h with 10 ng/ml TNF-α to
mimic the neuroinflammatory environment of EAE
[63, 64] as well as stimulate EV release [44, 65]. EVs
were then isolated from the BMEC supernatant and
resolved into exosome and microvesicle subtypes by
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differential centrifugation using a combination of estab-
lished protocols [39, 66]. The BMEC supernatant was se-
quentially spun at 300×g for 10 min at 4 °C, 2000×g for
10 min at 4 °C using a swing-bucket rotor and Eppendorf
5804R centrifuge (Eppendorf, Hauppauge, NY), and finally
8000×g for 30 min at 4 °C in a fixed-angle rotor and
Sorvall RC-5C Plus centrifuge (Sorvall-Thermo Scientific,
Dubuque, IA) to remove whole cells, large cell fragments,
and apoptotic bodies, respectively. The clarified super-
natant was then spun at 20,000×g for 30 min at 4 °C to
pellet EVs of larger microvesicle-size and the resulting
supernatant spun again at 60,000×g for 30 min at 4 °C to
pellet smaller-size microvesicles and possible exosome
aggregates using a Beckman TL-100 ultracentrifuge
(Beckman Coulter, Indianapolis, IN). The post-60,000×g
supernatant was then spun at 100,000×g for 60 min at
4 °C to pellet exosome-size EVs. Validation of the respective
EV subtypes was performed using high-resolution particle-
size profiling with a nanoparticle tracking analysis (NTA)
device (NS300; Malvern Instruments, Westborough, MA)
(Additional file 2: Figure S2). In some cases, “total” EVs
containing both exosomes and microvesicles were isolated
by centrifuging the clarified supernatant (generated
after sequential 300×g, 2000×g, and 8000×g spins) directly
at 100,000×g for 60 min.
Co-isolation of leukocytes and EVs (exosomes and
microvesicles) from blood
Both EVs and PBLs were isolated from the same popula-
tion of mice with EAE at D8 post-induction, a time at
which significant physical disruption of the BBB is not
yet apparent [67]. A total of 10 mice were used for each
preparation. Mice were anesthetized by intraperitoneal
injection of ketamine (80 mg/kg) and xylazine (10 mg/kg)
in phosphate-buffered saline (PBS). A 3 ml syringe with a
25 gauge needle was briefly flushed with 0.109 M (3.2%)
sodium citrate (BD, Franklin Lakes, NJ), and blood was
slowly acquired using transcardiac puncture. A total of
3 ml of fresh anticoagulant-treated blood was diluted 1:1
with Hank’s Balanced Salt Solution (HBSS; ThermoFisher
Scientific, Grand Island, NY) at 25 °C by gently inverting
the tube and slowly layered on 3 ml of Ficoll-Paque PLUS
(Sigma-Aldrich, St. Louis, MO) in a 15 ml Falcon tube.
Samples were spun at 400×g for 40 min at 25 °C in a
swing-bucket centrifuge (Eppendorf 5804R) without accel-
eration or brakes.
The “buffy” coat layer from the Ficoll-Paque PLUS
gradient was aspirated using a 1 ml pipette, washed in
three volumes of HBSS, and spun at 400×g for 10 min.
After discarding the supernatant, 1 ml of RBC lysis buf-
fer was added to each tube to eliminate RBC contamin-
ation and incubated for 5 min at 25 °C. The sample was
then neutralized with three volumes of HBSS and spun
at 400×g for 10 min. The pellet was resuspended in
HBSS and the gradient-purified leukocytes used for
Western blot analysis and immunocytochemistry.
The upper layer from the Ficoll-Paque PLUS gradient,
containing plasma, was used for EV (exosome and micro-
vesicle) isolation. Plasma was subject to the same differen-
tial centrifugation protocol as performed on the BMEC
supernatant.
Western blotting
Isolated leukocytes and EVs were solubilized in 8 M urea
containing protease inhibitor cocktail (Sigma-Aldrich, St.
Louis, MO). Protein concentration was assayed by the
Micro BCA protein assay kit (ThermoFisher Scientific,
Grand Island, NY). Lysates containing 10–30 μg leukocyte
protein, or 10 μg of EV protein, were separated by electro-
phoresis on 4–20% Mini-PROTEAN® TGX™ Precast
SDS-PAGE gels and transferred onto PVDF membranes
(Bio-Rad Laboratories, Hercules, CA). Membranes were
then blocked with 5% bovine serum albumin (BSA) in
Tris-buffered saline with Tween-20 (TBST) (Thermo-
Fisher Scientific, Grand Island, NY) for 1 h at room
temperature, followed by incubation overnight at 4 °C
with the CLN-5 antibody (1:200; Life Technologies,
Carlsbad, CA) diluted in 5% BSA in TBST. Following
incubation with anti-mouse HRP-conjugated secondary
antibody (1:400; Cell Signaling), blots were developed
using the chemiluminescent HRP substrate kit (SuperSignal
West Pico Chemiluminescent Substrate, ThermoFisher
Scientific, Grand Island, NY) and signal detected using
a G:Box XX6 digital gel imager (Syngene, Frederick, MD).
Images were acquired by GeneSys software (Syngene,
Frederick, MD).
Quantitative RT-PCR
Total RNA was extracted from cells using the comple-
mentary DNA (cDNA) direct lysis buffer. cDNA was
synthesized from the total RNA using a SuperScript III
first-strand synthesis system for RT-PCR with a standard
protocol. Measurements of cDNA levels were performed
by quantitative RT-PCR. Relative claudin-5 gene expres-
sion values were expressed as percentage of RPL-19, as
described previously [59].
High-resolution 3D imaging of CLN-5+ leukocytes
D9 EAE was selected for immunohistological analysis of
early leukocytic infiltrates into the CNS as this time
point has been previously reported to display the earliest
signs of focal increase in perivascular cellularity repre-
senting infiltrating leukocytes in spinal cord microvessels
[67]. Tissue processing, immunofluorescent staining of
60-μm-thick cryosections, and high-resolution imaging
of inflamed microvessels along with the associated perivas-
cular infiltrates in confocal z-stack images were performed
using a Zeiss LSM 510 Meta confocal microscope
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equipped with a 100x plan-apochromatic oil immersion
lens, 1.4 NA as detailed previously [58, 67]. Alexa® 488-
conjugated CLN-5 antibody (Clone 4C3C2, Life Technolo-
gies, Carlsbad, CA) was used for immunostaining. Isolated
leukocytes were plated on poly-L-lysine-coated eight-well
chamber slides (ThermoFisher Scientific, Grand Island,
NY), immunostained, and imaged similarly to sections.
Image analysis of EV:leukocyte binding
Exosome- and microvesicle-size EVs were separately la-
beled with green fluorescent membrane dye PKH-67
(Life Technologies, Carlsbad, CA). For binding studies,
PBLs were isolated from naïve mice using an Acrodisc®
white blood cell syringe filter (Pall Life Sciences, Port
Washington, NY), as this procedure was faster than gra-
dient purification and allowed for heightened viability.
Freshly isolated PBL leukocytes were labeled with red
fluorescent membrane dye, PKH-26 (Life Technologies).
PKH-67-labeled EVs were added to PKH-26-labeled
leukocytes in 500 μl microfuge tubes (ThermoFisher
Scientific, Grand Island, NY) and mixed overnight in
Ca2+/Mg2+-free HBSS supplemented with 2% exosome-
depleted bovine serum (System Biosciences) at 4 °C using a
360° rotator (Barnstead/ThermoFisher Scientific). Following
HBSS wash, the leukocyte-EV complexes were spun down
at 400×g to remove any unbound EVs. The leukocyte-EV
complexes were allowed to settle for an additional 2 h on
poly-L-lysine-coated eight-well chamber slides (Thermo-
Fisher Scientific, Grand Island, NY) for imaging. Adherent
leukocyte-EV complexes were fixed in 2% paraformal-
dehyde in PBS. High-resolution images were acquired
using 63x plan-neofluar oil immersion lens, 1.25 NA, as
described above for 3D imaging of CLN-5+ leukocytes
in spinal cord sections. All binding reactions were set
up between leukocytes from naïve mice and EVs from
mice at D8 EAE. The reasoning for this design was that
activated leukocytes from mice with EAE might be nearly
saturated with previously bound EVs in vivo and thus
might display minimal binding in vitro, while EVs released
during neuroinflammation might be more likely to express
CLN-5.
Bone marrow chimeras
Six-week-old C57BL/6J Tie-2-eGFP-CLN-5 transgenic
mice (CD45.2) were lethally irradiated (1000 rad) to
achieve myeloablation. Six hours later, hematopoietic
reconstitution was performed by retro-orbital adminis-
tration of 200 μl sterile PBS containing 1 × 107 bone
marrow cells derived from the femur and tibia of adult,
wild-type (WT) congenic C57BL/6J mice (CD45.1/CD45.2).
At approximately 9 weeks after bone marrow reconsti-
tution, peripheral blood chimerism was assessed by
fluorescence-activated cell sorting (FACS) analysis of
tail blood samples.
FACS analysis
Detection of CLN-5-immunostained PBLs
PBLs were isolated from WT mice blood at D8 post-
EAE using Acrodisc® white blood cell syringe filter (Pall
Life Sciences, Port Washington, NY). Following 4% PFA
fixation, PBLs were either left unpermeabilized or perme-
abilized with 0.2% Triton X-100 for 30 min and incubated
overnight at 4 °C with anti-CLN-5-Alexa® 488 antibody
(1:150; Life Technologies, Carlsbad, CA). Unlabelled PBLs
and PBLs incubated with Alexa® 488-conjugated isotype
controls were used for compensation. The intensity of
CLN-5 immunostaining in PBL suspensions with or
without permeabilization was analyzed on a FACS LSR
II (Becton Dickinson, Franklin Lakes, NJ). Data analysis
was performed with FlowJo software version 9 (Treestar,
Ashland, OR).
Detection of eGFP-CLN-5+ PBLs
PBLs were obtained from blood of Tie-2-eGFP-CLN-5
mice with EAE and the FACS analysis performed in a man-
ner similar to that described for CLN-5 immunostaining.
Analysis of peripheral PBL chimerism
Efficient reconstitution of the chimeric mice was con-
firmed by determining percentage donor CD45.1+ CD45.2+
cells in the blood of irradiated Tie-2-eGFP-CLN-5 mice.
Approximately 100 μl blood was collected from anesthe-
tized mice via tail bleed and RBC contamination elimi-
nated using RBC lysis buffer. Following neutralization of
the sample with HBSS, PBLs were obtained by centrifu-
gation, 400×g for 10 min. PBLs were resuspended in
PBS containing 2% FCS at 4 °C and stained with anti-
CD45.1-FITC, anti-CD45.2-APC (both from Tonbo Bio-
sciences, San Diego, CA), and anti-CD3-eF450 (eBios-
ciences, San Diego, CA). Cell suspensions were analyzed
by FACS as described for CLN-5-immunostained and
eGFP-CLN-5+ PBLs.
FACS sorting eGFP-CLN-5+ EVs and FACS analysis of
eGFP-CLN-5+ EV:PBL binding
A FACSAria™ II (BD Biosciences, San Jose, CA) was used
to sort eGFP-CLN-5+ EVs from the BMEC culture super-
natant or blood plasma of Tie-2-eGFP-CLN-5 transgenic
mice. A 130 μm nozzle and low 10 PSI sheath pressure
were used while running at the slowest sample speed, so
as to reduce the size of the sample core stream while
maximizing laser excitation of small particles. Nano-
fluorescent beads (Spherotech, Lake Forest, IL) were
used to determine the limit of detection of submicron
particles using both side scatter and green fluorescence
detectors and to gate on events that lay outside of “noise.”
For binding analysis, EVs alone (either isolated from the
Tie-2-eGFP-CLN-5 mice or PKH-67-labeled EVs isolated
from WT mice with EAE) and PKH-26-labeled PBLs
Paul et al. Journal of Neuroinflammation  (2016) 13:292 Page 5 of 17
alone were used to compensate for the respective un-
bound populations. Leukocytes were gated to omit deb-
ris events based on forward and side light scatter. Single
leukocytes were defined as having one forward scatter
pulse width per forward scatter trigger (Additional file 3:
Figure S3). Percentage(s) of double-positive events was
considered as a relative measure of EV:PBL binding.
Serial electron microscopy (serial EM)
Serial EM was performed as previously detailed [68, 69].
Mice were anesthetized with ketamine/xylazine and
transcardially perfused first with PBS to wash off the
blood and then with 2.5% glutaraldehyde and 2.0% para-
formaldehyde in 0.1 M cacodylate buffer through the left
ventricle of the heart. The spinal cord was isolated by
laminectomy and fixed for an additional 3–4 h in the
same fixative and then rinsed and stored in 0.1 M caco-
dylate buffer at 4 °C until further processing. The lum-
bar section of the spinal cord was cut with a razor blade
into ~1 mm-thick slices and rinsed in 0.1 M cacodylate
buffer several times. The samples were processed using
the ROTO protocol [70] and then dehydrated in graded
ethanol solutions and embedded in epoxy resin (Polybed
Polysciences, Warrington, PA).
After the samples were polymerized, the face of each
block was shaped to a ~2 × 3 mm rectangle using a dia-
mond trimming knife. Thin sections, 60 nm thick, were
cut using a microtome (Leica EM UC7, Buffalo Grove, IL)
and a diamond knife. Serial sections were collected on
Kapton tape (glow-discharged to minimize wrinkling of
sections) using the ATUM tape collector [71]. The tape
with sections was cut into strips and mounted on 4 in. sili-
con wafers (University Wafers, South Boston, MA) and
then carbon-coated for electron grounding (Denton 502B,
Moorestown, NJ).
Sections were imaged using a field emission scanning
EM (Zeiss Sigma FE-SEM; Peabody, MA) in backscatter
mode (10 keV electrons, ~5 nA beam current). A high-
precision map of the sections on the wafer (±4 μm) was
generated, and then, the Atlas Large Area Imaging
software (Fibics Inc., Ottawa, Ontario, Canada) was used
to automatically image a ~65 μm× 65 μm field of the
serial sections at 5–7 nm/pixel resolution (12,288 ×
12,288 pixels). The images were aligned using the
Linear Alignment with SIFT algorithm (FIJI, ImageJ)
and reconstructed using Imaris®.
3D contour surface creation of serial EM slices using
Imaris
To visualize the endothelium and possible EVs at the site
of leukocyte adhesion in 3D, the serial EM slices were
first imported into Imaris for volume rendering. Manual
contour tracing was then performed by cursoring out
the endothelium, EV-like structures and the adherent
leukocyte(s) of interest in each serial EM z-slice and the
individual contours merged into a 3D contour surface,
as detailed previously [58, 72].
Results
Presence of CLN-5+ leukocytes within the CNS during EAE
To view CLN-5+ leukocytes in the CNS during neuroin-
flammation, spinal cord sections of WT mice at D9
post-EAE induction—during the pre-clinical phase of
disease—were immunostained and analyzed by high-
resolution 3D fluorescence microscopy. This time point
was specifically selected in case CLN-5+ leukocytes
operate early in the extravasation process that drives
pathogenesis—before substantial BBB disruption. Immu-
nostaining of microvessels revealed the typical “chicken
wire” pattern of CLN-5 along inter-endothelial cell
borders [58, 67]. Additionally, leukocytes labeled with
anti-CLN-5 were obvious within perivascular infiltrates
surrounding inflamed vessels (Fig. 1; Additional file 4:
Video 1) and revealed punctate immunostaining patterns
Fig. 1 CLN-5+ leukocytes are present in the CNS during early EAE. z-stack confocal images acquired from the same spinal cord cryosection of a WT
mouse at D9 EAE are shown. a Immunostaining of TJ protein CLN-5 (green) and CD31 (red) to identify endothelial cells, showing CLN-5 is present on
both leukocytes and at endothelial junctions. b DRAQ5 staining (blue) highlights the cellularity associated with CNS-infiltrating leukocytes, revealing
CLN-5+ leukocytes (green) comprise a subset of invading cells. c Immunostaining of TJ protein CLN-5 only; arrows (yellow) indicate some CLN-5+
leukocytes are associated with areas of discontinuity of CLN-5 junctional staining. Leukocyte-associated CLN-5 immunoreactivity displays a
punctate appearance
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that seemingly covered the cells. These CLN-5+ leukocytes
were mostly visible along the meningeal microvessels and
the infiltrating parenchymal vessels at this early time point
in EAE (Additional file 5: Figure S4). CLN-5+ leukocytes
also appeared to concentrate in regions proximal to focal
discontinuities in vascular CLN-5 immunoreactivity that
might reflect subtle changes in BBB integrity. Despite
their obvious detection, CLN-5+ leukocytes constituted
only a fraction of the invading leukocyte population.
This laboratory previously found no evidence of CLN-5+
leukocytes—or any perivascular infiltrates—in spinal cord
microvessels from naïve mice during an exhaustive ana-
lysis of CLN-5 distribution using the same identical stain-
ing and image acquisition parameters described in this
report [58]. Appearance of CLN-5+ leukocytes thus ac-
companies early infiltrates during disease.
Detection of circulating CLN-5+ leukocytes (PBLs) during
EAE
Next, the presence of CLN-5+ leukocytes in the circulation
was evaluated. A similar, punctate, CLN-5 immunostaining
pattern was seen on PBLs from mice with EAE as was ob-
served on leukocytes in the CNS (Fig. 2a). This pattern was
further observed in both detergent-permeabilized and non-
permeabilized cells, consistent with the interpretation that
the immunoreactive CLN-5 epitope is at least partially
present on the cell surface. FACS analysis corroborated the
imaging results, additionally revealing higher staining in-
tensity in the permeabilized samples, wherein antibody
may also access intracellular CLN-5 (Fig. 2b). To further
assure these CLN-5+ cells were leukocytes and not circulat-
ing endothelial cells, PBLs were double-stained for CLN-5
and common leukocyte antigen, CD45 (Additional file 6:
Figure S5). Though co-localization of CLN-5 and CD45
immunostaining was obvious in many cases, cells that
brightly stained for CLN-5 showed a reduced intensity for
CD45. This could possibly be due to steric hinderance be-
tween the antibodies, as double staining was best observed
when cells were incubated with both antibodies simultan-
eously rather than sequentially (data not shown). Western
blotting confirmed the expression of CLN-5 protein at the
expected apparent Mwr of approximately 23 kDa (Fig. 2c).
In addition to displaying CLN-5 protein, PBLs also
demonstrated CLN-5 gene expression (Additional file 7:
Figure S6). CLN-5 expression was detected even in PBLs
from naïve mice but was significantly upregulated by D8
EAE and then decreased by D13.
Endothelial origin of CLN-5 on leukocytes
Because expression of TJ proteins is typically reserved
for endothelial and epithelial cells, the appearance of these
proteins on leukocytes is regarded as ectopic [19]. Accord-
ingly, the next experiments addressed whether endothelial
cells—with which leukocytes come in intimate contact
Fig. 2 CLN-5+ leukocytes in circulation during early EAE. a Representative z-stack confocal images of PBLs isolated from WT mice at D8 EAE and
immunostained with CLN-5 (green isosurface) under non-permeabilized or permeabilized (with Triton X-100) conditions. Leukocytes were obtained
a day earlier than in Fig. 1, to ensure those CLN-5+ cells in the circulation had not yet all extravasated. b FACS analysis of leukocytes from D8 EAE
mice immunostained with the same antibody shows CLN-5 staining under both non-permeabilized and permeabilized conditions. Leukocytes
stained with an isotype antibody were used as control. c Western blot analysis of lysates from the same batch of leukocytes and the same antibody
clone used in a and b showing a 23 kDa molecular weight band, consistent with the molecular weight of CLN-5
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during inflammation—might be the likely origin of
leukocyte-associated CLN-5. To verify endothelial ori-
gin of CLN-5 on leukocytes, Tie-2-eGFP-CLN-5 mice
that demonstrate targeted expression of eGFP-CLN-5
in all endothelial cells [57] were used. First, localization
of the eGFP signal at endothelial cell-cell junctions was
confirmed in BMEC cultures (Additional file 1: Figure S1)
and spinal cord cryosections from naïve Tie-2-eGFP-CLN-5
mice (Fig. 3a). The eGFP signal demonstrated an identical
chicken wire distribution with anti-CLN-5 staining, under-
scoring both staining patterns reflect TJ-associated CLN-5.
No infiltrating eGFP-CLN-5+ cells or other cellular in-
filtrates were seen in the perivascular spaces surround-
ing penetrating or parenchymal venules in naïve mice,
consistent with the prior report from this laboratory
documenting absence of immunostained CLN-5+ leu-
kocytes and infiltrates from healthy CNS tissue [58].
Next, the appearance of eGFP-CLN-5+ leukocytes in the
CNS was evaluated in Tie-2-eGFP-CLN-5 mice with EAE.
Figure 3a shows eGFP-CLN-5+ leukocytes in the perivas-
cular locale within the CNS, alongside an eGFP-CLN-5+
microvessel. Like that observed with anti-CLN-5 stain-
ing, the eGFP signal on leukocytes had a punctate dis-
play and appeared to cover the cells. Additionally,
eGFP-CLN-5+ leukocytes—as for anti-CLN-5-stained
leukocytes—represented only a fraction of the perivas-
cular infiltrate and were absent from the CNS of naïve,
Tie-2-eGFP-CLN-5 mice. This was in accord with a low
fraction of eGFP-CLN-5+ PBLs (1.2%) in the blood of
Tie-2-eGFP-CLN-5 mice at D8 post-EAE (Fig. 3b).
To discount the possibility that the eGFP signal on
leukocytes arose solely from endogenous expression of
eGFP-CLN-5, due to some Tie-1 promoter activity in de-
veloping hemopoietic cells [73–75], analysis was repeated
in bone marrow chimeras generated from non-transgenic
donor (CD45.1/45.2) and lethally irradiated Tie-2-eGFP-
CLN-5 recipient (CD45.2) mice. As shown in Fig. 4a, ap-
proximately 98% of circulating T cells in the chimeras was
found to be CD45.1+ CD45.2+, indicating successful
substitution of the leukocyte population of recipient
Tie-2-eGFP-CLN-5 mice with that of donor mice. As
leukocytes of chimeric mice are virtually exclusively
donor-derived and, hence, lack the ability to endogen-
ously express Tie-2 promoter-driven eGFP-CLN-5, the
appearance of eGFP-CLN-5+ leukocytes in chimeras
would reinforce the argument that the eGFP signal from
these cells is endothelial in origin. Figure 4b, c and
Additional file 8: Video 2 show that, as with Tie-2-
eGFP-CLN-5 mice, chimeras displayed eGFP-CLN-5+
leukocytes within both the blood and CNS following
Fig. 3 Appearance of eGFP-CLN-5+ leukocytes in Tie-2-eGFP-CLN-5 mice during EAE. a z-stack confocal images acquired from spinal cord cryosections
from Tie-2-eGFP-CLN-5 mice showing distribution of eGFP-CLN-5 (green) in naïve venules and associated with an inflamed venule and perivascular
leukocytes at D9 EAE. Inset shows DRAQ staining (blue) highlighting the extent of perivascular cellularity, representing leukocyte infiltrates and a
minority fraction of eGFP-CLN-5+ leukocytes. The presence of eGFP-CLN-5+ leukocytes in the CNS is consistent with these cells having acquired
eGFP-CLN-5 from endothelial sources. b PBLs were isolated from Tie-2-eGFP-CLN-5 mice (n = 5) at D8 post-EAE induction and then subjected
to FACS analysis and percentage eGFP-CLN-5+ CD45+ recorded (right). Control PBLs from naïve, WT mice were used to set the gate (left)
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EAE induction. The eGFP-CLN-5+ leukocytes in the
CNS of chimeric mice again comprised a minor fraction
of the extravasated cells and were further observed to ag-
gregate, perhaps reflecting the ability of their CLN-5 to
self-associate. Collectively, these findings suggest that a se-
lect population of leukocytes invading the CNS during
neuroinflammation acquires CLN-5 in part from endothe-
lial cells, and this acquisition occurs in blood.
Expression of CLN-5 by endothelial-derived EVs
To next examine if endothelial-derived EVs might act as
potential sources of CLN-5 for leukocytes, expression of
this protein was evaluated in isolated EV populations.
First, “total” EVs (combined exosome- and microvesicle-
sized-EVs) were isolated by differential centrifugation
from the supernatants of cultured BMEC stimulated with
TNF-α, a pro-inflammatory cytokine associated with EAE
[63, 64] and a known inducer of endothelial EV release
[44, 65]. The total EV pellet, as well as a lysate of the
endothelial monolayer culture, expressed CLN-5 protein,
as detected by Western blotting (Fig. 5a). TNF-α appeared
to only modestly increase the amount of detectable CLN-
5+ EVs released by BMEC (Additional file 9: Figure S7), in-
dicating these are constitutively shed from these cells in
culture. Further fractionating the EVs into exosomes and
microvesicle-size vesicles, respectively, showed EV sub-
types of both sizes expressed CLN-5 (Fig. 5b). FACS ana-
lysis of total EVs isolated from plasma of Tie-2-eGFP-
CLN-5 mice with EAE additionally showed a fraction
of these vesicles (0.4%) to be eGFP-CLN-5+ (Fig. 5c),
suggesting their possible derivation from endothelial
cells in vivo.
Binding of endothelial-derived EVs to leukocytes
Having demonstrated endothelial-derived CLN-5 on both
leukocytes and EVs, we next addressed whether EVs, in
general, could bind to leukocytes—a fundamental action if
EVs serve as physiological vehicles for endothelial-to-
leukocyte transfer of CLN-5. EVs were again isolated from
the cultured supernatant of TNF-α-stimulated BMEC and
separated by differential centrifugation into exosome- and
microvesicle-size fractions. The separate EV fractions were
labeled with PKH-67 dye and incubated with PBLs ob-
tained from naïve mice and labeled with PKH-26 dye.
Evaluation by image analysis revealed both EV populations
bound to leukocytes (Fig. 6a). FACS analysis confirmed
this binding, as reflected by double-positive events, and
further indicated a range of 4.5–7% of leukocytes bound
Fig. 4 WT/Tie-2-eGFP-CLN-5 chimeras highlight endothelial origin of leukocyte CLN-5. Bone marrow cells from WT, non-transgenic donor mice
(CD45.1/CD45.2) were transplanted into lethally irradiated about 6-week-old Tie-2-eGFP-CLN-5 host mice (CD45.2) via retro-orbital injection. a At
10 weeks post-transplant, tail bleeds were performed to assess the efficacy of leukocyte substitution. FACS shows PBLs from non-irradiated, host
eGFP-CLN-5 mice are all CD45.2+ (left), while those in chimeras are approx. 98% CD45.1+ CD45.2+ (right), indicating host PBLs were nearly entirely
replaced. b Two days following confirmation of leukocyte substitution, EAE was induced in chimeras and age-matched non-irradiated, host
eGFP-CLN-5 mice (at approx. 16 weeks of age; n = 4). At D8 EAE, PBLs were isolated from both groups of mice and percentages of eGFP-CLN-5+
CD45+ determined. Control PBLs from naïve, WT mice and PBLs labeled with isotype control antibodies were used to set the gates (data not shown).
c z-stack confocal image from the spinal cord section of chimeric mouse at D9 EAE showing eGFP-CLN-5 (green) distribution along the intercellular
boundaries of a CNS microvessel (arrows) and associated with an aggregate of perivascular leukocytes (arrowhead). Insert shows high-power field
of aggregated eGFP-CLN-5+ leukocytes
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to EVs in vitro (Fig. 6b). The binding of total PKH-67-
labeled EVs to PKH-26-labeled leukocytes also appeared
saturable (Fig. 6c), as it was sensitive to competition by
excess of unlabeled EVs. Specifically, the percentage of
leukocytes binding labeled EVs diminished ~93%, while
the PKH-67 signal intensity per leukocyte (mean fluores-
cence intensity), a reflection of the relative EV binding/
cell, fell ~65%.
To further explore if CLN-5+ EVs, in particular, could
bind to leukocytes, total EVs (exosome- and microvesicle-
size) were first isolated from plasma of Tie-2-eGFP-CLN-
5 mice at D8 EAE and then eGFP-CLN-5+ EVs FACS-
purified from this population for EV:leukocyte binding. As
was the case with PKH-labeled EVs derived from BMEC,
eGFP-CLN-5+ EVs obtained from plasma were observed
to bind to leukocytes (Fig. 6d). Since these EVs could the-
oretically have been released into the circulation from any
endothelial cells in the body, eGFP-CLN-5+ EVs were
additionally isolated from culture supernatants of TNF-
α-stimulated BMEC derived from Tie-2-eGFP-CLN-5
mice. EVs from this source, too, bound to leukocytes in
vitro (data not shown), supporting the concept endo-
thelial cells of the BBB, specifically, can shed CLN-5+
EVs capable of attaching to leukocytes.
“EV-like” structures at the BBB endothelium and site of
leukocyte attachment in situ
Serial EM combined with 3D rendering was next used in
an effort to try and capture EVs in association with leuko-
cytes at the BBB in situ. Figure 7a, b shows an inflamed
venule containing marginating leukocytes at various stages
of extravasation, along with what appear as “EV-like” struc-
tures, ranging in size from ~100 nm to <1 μm, located be-
tween the leukocytes and the endothelium. These EV-like
structures can also be seen in close approximation to the
endothelial glycocalyx, as well as just subjacent to the
endothelial plasma membrane (Fig. 7e). A 3D contour sur-
face creation of a group of EV-like structures (Fig. 7c–e)
depicts them as an aggregate seemingly partially
enveloped—in an apparent “umbrella-like” manner—by a
closely associated leukocyte (Fig. 7d). An oblique view of the
rendered site of leukocyte:endothelial attachment further
portrays the aggregate of EV-like structures as penetrating
the endothelial surface, possibly reflecting a close continuity
with nascent EVs (Fig. 7c; Additional file 10: Video 3).
Discussion
This study established the presence of CLN-5+ leukocytes
in the CNS during neuroinflammation and identified
Fig. 5 CLN-5+ expression in endothelial-derived EVs. a, b Western blot analysis of CLN-5 in EVs from supernatants of TNF-α-treated BMEC cultures.
Total EVs (a) and exosome- and microvesicle-size EVs separated by differential ultracentrifugation (b), showing a 23 kDa molecular weight band
consistent with the molecular weight of CLN-5. c FACS analysis of total EVs isolated from blood plasma of Tie-2-eGFP-CLN-5 mice with EAE, showing
eGFP-CLN-5+ EVs alone (left) or eGFP-CLN-5+ EVs co-stained with PKH-26 dye to label all (eGFP-CLN-5+ and eGFP-CLN-5−) EVs (right), in the double-
positive event gate. Approx. 0.4% of all blood-derived EVs are shown as eGFP-CLN-5+ PKH-26+. Nano-fluorescent-size standard beads (not shown) were
used for setting the gates
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endothelial cells to be a source for this ectopic expres-
sion of CLN-5. Specifically, leukocytes bearing CLN-5
protein were observed in the blood and spinal cord of
WT mice with EAE. The occurrence of eGFP-CLN-5+
leukocytes in the blood and CNS of Tie-2-eGFP-CLN-5
mice suggested the leukocyte eGFP signal can originate
in part from endothelial cells. Endothelial contribution
of eGFP was confirmed in chimeric mice, in which the
endogenous leukocyte population of Tie-2-eGFP-CLN-
5 mice was replaced with bone marrow-derived cells
from non-transgenic mice, so as to preclude any trans-
genic Tie-2 activity in the leukocyte population of the
recipients. The appearance of eGFP-CLN-5+ leukocytes
in these chimeric mice is consistent with a transfer of
eGFP-CLN-5 from endothelial cells to circulating leu-
kocytes. Studies additionally demonstrated circulating
EVs from mice with EAE, as well as EVs released from
TNF-α-stimulated cultured BMEC, contained CLN-5
and could bind to leukocytes in vitro. In situ analysis by
serial electron microscopy further revealed what appear
to be EV-like structures enveloped by leukocytes mar-
ginating along the CNS microvascular endothelium.
Collectively, these findings allude to a possible scenario
during neuroinflammation, wherein endothelial cells at
the BBB release CLN-5+ EVs that subsequently bind to
leukocytes in a juxtacrine manner (Fig. 8).
The present work extends the report of Mandel et al.
[20, 21], which noted an increase in CLN-5+ leukocytes
in blood from MS patients who experienced disease re-
lapse. Our findings corroborated the presence of CLN-5+
leukocytes in blood during EAE, an animal model of MS
[54–56], and further demonstrated their appearance in the
CNS. The presence of these cells in both blood and CNS
relatively early during disease (D9 EAE) suggests it un-
likely they acquire CLN-5 as a consequence of extravasa-
tion or only when there is substantial BBB breakdown
later in the chronic phase [58, 67]. Specifically, these find-
ings argue against CLN-5+ leukocytes arising merely as a
result of having passively picked up CLN-5 remnants of
proteolyzed endothelial TJs that may have been deposited
abluminally [76]. An alternative scenario is leukocytes ac-
quire CLN-5 from endothelial cells while in the circula-
tion as a prelude to extravasation. Anecdotal support for
this endothelial-to-leukocyte transfer hypothesis is further
Fig. 6 EVs from endothelial cells bind to leukocytes in vitro. a–c EVs collected from supernatants of TNF-α-treated BMEC cultures were incubated
with isolated PBLs. a z-stack confocal images show PKH-67-labeled (green) exosome- and microvesicle-size EVs separated by differential
ultracentrifugation can bind to PKH-26-labeled naïve PBLs (red), along with DRAQ5 staining of PBL nuclei (blue). Insets highlight co-localization of
staining on a single PBL. b–c Binding of total PKH-67-labeled EVs to naïve PBLs. FACS analysis revealed 4.5% of the PBLs were PKH-26+ PKH-67+
(double-positive), suggestive of binding. The percentage of PBLs binding to PKH-67+ EVs diminished by 93%, while the PKH-67 signal intensity per
leukocyte (mean fluorescence intensity), a reflection of the relative EV binding/cell, decreased by 65% in the presence of a 500-fold excess of unlabeled
EVs. d Total eGFP-CLN-5+ EVs, FACS-purified from blood plasma of Tie-2-eGFP-CLN-5 mice at D8 EAE, bind to naïve PBLs in vitro. In this case, PBLs are
identified by CD45 staining (blue). Inset further highlights a punctate binding pattern of eGFP-CLN-5+ EVs to PBLs
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provided by observations of Mandel et al. [20] who noted
that, while levels of CLN-5 were elevated in PBLs of MS
patients in the relapse state, CLN-5 status was unaffected
by in vitro activation of these cells. The authors concluded
that upregulation of CLN-5 by leukocytes in MS reflects
interaction of these cells with “additional cell types.” That
expression of CLN-5 by PBLs from MS patients was di-
minished following successful anti-inflammatory therapy
is also consistent with the argument that acquisition of
CLN-5 by leukocytes is not merely a result of leukocyte
extravasation but, rather, occurs prior to it—while the cells
are still in the blood.
Acquisition of CLN-5 by leukocytes in the blood would
also be in line with endothelial-to-leukocyte transfer of
this protein being mediated by EVs. That both total EVs as
well as CLN-5+ EVs bound to leukocytes in vitro further
underscores the feasibility of such a transaction. Also,
lending support are reports by Takahashi et al. [40] and
Haqqani et al [39] that cultures of human aortic endothe-
lial cells and human BMEC, respectively, release EVs con-
taining junctional proteins. Most recently, Andrews et al.
[41] described the release from cultured human BMECs
of EVs containing the TJ protein occludin, following
application of mechanical trauma to these cells, and
Fig. 7 EV-like structures in situ at sites proximal to leukocyte adhesion. Serial EM images from mouse spinal cord sections obtained at D13 EAE. a
Single serial section showing cross section of an inflamed venule highlighting adherent leukocytes, some apparently undergoing TEM. Inset highlights
EV-like membrane-bound structures (blue arrowhead) at the leukocyte-endothelial interface of an adherent leukocyte (blue box). b Representative 3D
reconstruction of an adherent leukocyte shown in a, generated from 130 serial slices. The larger membranous structure indicated by * is on the order
of 1 μm in diameter and may represent an apoptotic body loosely tethered to the leukocyte. c Contour surface reconstruction of the “traced” leukocyte
(red), EV-like structures (green), and endothelium (turquoise) in all 130 serial slices, providing a 3D view of all three elements at the site of leukocyte
docking (yellow asterisk). Inset provides an oblique view of the site of leukocyte attachment, showing EV-like structures and leukocyte process (yellow
arrowheads) apparently below the surface of the endothelial plasma membrane. d, e 3D surface reconstruction of the leukocyte in panels a–c, along
with a representative serial EM slice, highlighting various patterns and sizes of EV-like structures, close to the site of leukocyte binding
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additionally noted EVs bearing this protein were elevated
in blood plasma of mice subject to traumatic brain injury
(TBI). Further paralleling our results for CLN-5+ vesicles,
these authors observed that occludin+ EVs stemming from
trauma were of both exosome and microvesicle size. As
mechanical trauma to the CNS microvasculature is also
associated with endothelial activation, immune reaction,
and neuroinflammation [77–79], BMEC release of EVs
carrying TJ proteins might be a general phenomenon
linked to CNS leukocyte infiltration. Notably, Andrews et
al. [41] also found the percent of occludin+ EVs in the
blood of TBI mice to be comparatively minor, e.g., <6% of
total EVs, compared to ~1% of CLN-5+ EVs detected in
mice with early-stage EAE. The slight discrepancies in the
observed percentages could be due to differences in the
experimental conditions employed, with TBI possibly be-
ing more disruptive to the vasculature. Also, FACS detec-
tion of EVs by forward scatter properties [41] versus side
scatter properties (this study) could have been a contribut-
ing factor as well. The relatively low level of CLN-5+ EVs
detected in the circulation is also in accord with their
being released focally from select endothelial cells,
rather than diffusely as part of a widespread endothelial
response.
It is further significant that only a fraction of leukocytes
(range 4.5–7%) was observed to bind to EVs in vitro, as
this qualitatively resembled the similarly limited popula-
tions of CLN-5-immunostained and eGFP-CLN-5+ leuko-
cytes observed in the CNS of EAE mice. This correlation
lends added credence to EVs being a major mode by
which leukocytes acquire CLN-5 and might further imply
only a specialized subset of leukocytes expresses or utilizes
binding sites for EVs. As binding of labeled EVs was also
sensitive to competition by an excess of unlabeled EVs,
binding sites for EVs on leukocytes appear to be saturable.
The identity of these sites is not yet clear but might in-
clude heparan sulfate proteoglycans, which are abundant
on leukocytes and have been shown to bind to EVs in a
manner inhibited by free heparan sulfate chains [80].
The binding to leukocytes of CLN-5+ EVs, in particular,
could potentially occur through another mechanism. Our
finding that leukocytes from naïve mice and those with
EAE express CLN-5 mRNA is in accord with a previous
observation of CLN-5 gene expression by circulating leu-
kocytes from both healthy controls and MS patients [20].
In turn, de novo expression of CLN-5 or other TJ proteins
by leukocytes might provide binding sites for endothelial-
derived CLN-5+ EVs. Even if only minimal TJ protein is
initially expressed on the leukocyte cell surface, this could
be sufficient for binding CLN-5+ EVs in a homophilic
and/or heterophilic manner. A modest elevation of en-
dogenous CLN-5 expression by leukocytes during neuro-
inflammation, as was seen here during EAE and in MS
patients during disease exacerbation [20], might further
stimulate binding. Such EV binding might allow for an
acute and significant increase in CLN-5 on the leukocyte
surface in response to local cues, such as endothelial acti-
vation and stimulated EV release at restricted sites. Ac-
quiring most of their CLN-5 in a temporally and spatially
restricted way would avert a need for leukocytes to en-
dogenously express significant amounts of CLN-5 protein
and the risk of extensively binding each other and forming
aggregates in the general circulation, as do other cell types
engineered to ectopically express CLNs [81]. It is sig-
nificant in this regard that although circulating leuko-
cytes from naïve mice display CLN-5 gene expression,
no CLN-5+ leukocytes—or any perivascular infiltrates—
were detected in the CNS of these animals. Apparently,
CLN-5 gene expression by leukocytes is not sufficient to
drive these cells’ entry into the CNS in the absence of
other cues. It is only within the context of neuroinflamma-
tion, and possibly the focal release and binding of
endothelial-derived CLN-5+ EVs, that CLN-5+ leukocytes
make their detectable CNS appearance.
While the functional significance of leukocytes display-
ing CLN-5 awaits clarification, appearance of these cells
Fig. 8 Interactions of endothelial CLN-5+ EVs with leukocytes. EVs
shed from endothelial cells could potentially transfer CLN-5 protein
to leukocytes and foster TEM by several conceivable scenarios: [1]
binding of shed CLN-5+ EVs to undefined sites on the leukocyte
surface, [2] binding of nascent CLN-5+ EVs still associated with the
endothelium to endogenous CLN-5 on the leukocyte surface, and
[3] binding of shed CLN-5+ EVs to endogenous CLN-5 on the leukocyte
surface, resulting in temporary cross-linking of leukocyte to the
endothelium. Binding of CLN-5+ EVs to endogenous CLN-5 on the
leukocyte surface could potentially amplify leukocyte:endothelial
interactions by increasing avidity of CLN-5-binding partners. Not
shown are possibilities EVs might inject endothelial-derived CLN-5
protein and/or mRNA into the leukocyte for surface expression.
Concentrated release of EVs near the junctional region could act in
a juxtacrine manner to guide leukocytes to this site for TEM
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in both blood and CNS satisfies a minimal criterion for
a zipper mechanism of TEM [15–18] to potentially oper-
ate in the CNS. A priori, a scenario wherein CLN-5 is
focally transferred from endothelial cells to marginating
leukocytes at the inflamed BBB, for the purpose of pro-
moting TEM through transient homophilic and/or het-
erophilic interactions between CLN partners on the two
cell types, is in accord with several lines of evidence.
Notable in this regard is that leukocyte adhesion to the
vascular wall is a stimulus for EV release [52], providing
for a tight coupling of leukocyte margination and EV re-
lease in space and time. Indeed, with the capability of
CLN-5+ EVs to act as multidentate ligands, their binding
to CLN-5 on leukocytes might allow for the type of cross
bridging depicted in Fig. 8, supporting enhanced oppor-
tunity for leukocyte and endothelial TJ protein partners
to engage through a zipper mechanism. This scheme
would endorse a juxtacrine interaction between leukocytes
at the luminal surface and nascent EVs and account for
the relatively low frequency of CLN-5+ leukocytes and
CLN-5+ EVs in the general circulation. Serial SEM obser-
vations of EV-like structures in situ interfaced between
leukocytes and endothelial cells at the BBB comport with
such a juxtacrine interaction. Lending added credence to
this hypothesis is the finding by Jimenez at al. [44] that
complexes of monocytes with EVs derived from TNF-α-
stimulated cultured human BMECs facilitated TEM across
an in vitro model of the BBB. The additional observation
that CLN-5+ leukocytes in the CNS tend to remain in
close proximity to vessels and not enter deep into the
parenchyma might further argue the action of these
cells is brief and largely confined to the extravasation
process itself. Making use of a zipper mechanism, CLN-5+
leukocytes might serve the role of “pioneers” to open the
BBB for other leukocytes to closely follow through
partially patent inter-endothelial junctions. Such a pio-
neering function would also be consistent with the modest
numbers of these cells found in the blood and CNS.
Characterization of CLN-5+ leukocyte function is beyond
the scope of this study and is currently being pursued by
this laboratory at several levels.
New roles for EVs in the CNS are continuing to
emerge [82], with EV-mediated RNA transfer from immune
cells to neurons [75] and from glioblastoma to microglia/
macrophages [83], both being demonstrated in the brain.
EVs derived from endothelial cells of the BBB, in particular,
have further garnered attention for their roles in neurode-
generative disease [84] and communication with other cell
types in the neurovascular unit [85]. It may further be that
reports of increased circulating TJ proteins following brain
trauma [86] and hemorrhage [87] actually reflect release
into the bloodstream of TJ protein+ EVs from an inflamed
and/or damaged BBB. Indeed, the propensity for EVs de-
rived from inflamed BMEC to self-aggregate [85] might be
a manifestation of TJ proteins on the EV surface. The
present studies offer a novel rationale for the increasing
association of EVs with neuroinflammation [88–93]. Spe-
cifically, endothelial-to-leukocyte transfer of CLN-5 and
other TJ proteins via EVs could be a basis for the ectopic
display by leukocytes of junctional components normally
restricted to specialized inter-endothelial/epithelial con-
tacts and potentially allow for a zipper mechanism for
leukocyte extravasation across the BBB. In this respect,
CLN-5+ EVs released from BMEC might “educate” leu-
kocytes in migratory behavior, paralleling what EVs
from tumor cells have been shown to do in stimulating
mobilization of bone marrow progenitor cells out of
their niche [94, 95]. As more factors are identified that
foster paracellular versus transcellular TEM [94] across
the BBB, EVs released by CNS endothelial cells might
be found to serve as additional determinants. Interest-
ingly, the recent observation of elevated circulating TJ
proteins associated with leukemia central nervous system
metastasis [96] may indicate tumor cells and leukocytes
share a common EV-mediated mechanism to cross the
BBB and other tight barriers. Further analysis of EV action
during neuroinflammation will aid in illuminating
pathogenic mechanisms and potential biomarkers of dis-
ease status, as well as offer new therapeutic prospects to
antagonize EVs or exploit their properties for molecular
delivery [97–101].
Conclusions
In summary, this study provides the first evidence of
CLN-5+ leukocytes within the CNS during the neuroin-
flammatory condition EAE. CLN-5+ leukocytes were also
observed in blood, paralleling findings described in MS
patients [20]. Endothelial cells were further determined to
be at least one source of this ectopic expression of CLN-5.
EVs bearing CLN-5 protein, either released into the circu-
lation during EAE or into the media of TNF-α-stimulated
BMEC cultures, bound to leukocytes in vitro, suggesting
EVs could act as vehicles for endothelial-to-leukocyte
transfer of CLN-5 protein at the BBB. Serial EM combined
with 3D rendering additionally showed EV-like structures
within the lumen of inflamed CNS microvessels, posi-
tioned between marginating leukocytes and endothelial
cells. Collectively, these findings could provide a basis for
a zipper mechanism to facilitate TEM into the CNS
through the formation of temporary TJ protein bridges
between leukocytes and endothelial cells at the BBB.
Additional files
Additional file 1: Figure S1. Cultured BMEC from Tie-2-eGFP-CLN-5
mice. z-stack confocal image of primary BMEC culture from Tie-2-eGFP-
CLN-5 mice, revealing TJ protein CLN-5 (green) at the inter-endothelial
regions and DRAQ5-stained nuclei (blue). (TIF 1.47 mb)
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Additional file 2: Figure S2. Nanoparticle tracking analysis of EVs. A
NS300 NTA was used to perform high-resolution particle-size profiling
and concentration measurements of exosome- (left) and microvesicle-size
particles (right) purified by differential centrifugation from the supernatant
of TNF-α-stimulated mouse BMEC culture. (TIF 1.28 mb)
Additional file 3: Figure S3. Gating strategy. (a–c) Gating for PBLs.
PBLs (circulating leukocytes) isolated from naïve WT mice were gated on
a forward scatter/side scatter (FSC-A/SSC-A) dot plot (a). These events
were next visualized using a FSC-W/FSC-H dot plot, and the singlets
(single cells) were gated (b). Following PKH-26 dye (red) labeling, single
PBLs were displayed on a PKH-26/PKH-67 dot plot (c). (d) Gating for EVs. For
detecting EVs, nano-fluorescent beads were first used to determine the limit
of detection of submicron particles using both side scatter and green
fluorescence detectors and to gate on events that lay outside of the
background. EVs labeled with PKH-67 (green) alone were used to set
gates for free/unbound EVs and shown on a PKH-26/PKH-67 dot plot.
(TIF 1.24 mb)
Additional file 4: Video 1. 3D perspective of CLN-5+ leukocytes in the
CNS during early EAE. 3D reconstruction of z-stack confocal images
shown in Fig. 1 reveals the 3D distribution of extravasated CLN-5+ (green)
leukocytes along an inflamed microvessel highlighted with CD31 (red)
staining. DRAQ5 staining (blue) highlights the perivascular cellularity,
showing CLN-5+ leukocytes comprise only a fraction of total CNS-infiltrating
leukocytes. (MP4 18.6 mb)
Additional file 5: Figure S4. CLN-5+ leukocytes along the meningeal and
parenchymal thoraco-lumbar spinal cord venules in EAE. z-stack confocal
images acquired from a thoraco-lumbar spinal cord cryosection of WT mice
at D9 EAE are shown, revealing staining for TJ protein CLN-5 (green), endo-
thelial CD31 (red), and nuclear DRAQ5. Regions A and B are shown to high-
light the emergence of CLN-5+ leukocytes along the meningeal
microvessels, whereas C underscores the TEM of CNS-infiltrating CLN-5+
leukocytes in parenchymal microvessels during EAE progression. (TIF 1.68 mb)
Additional file 6: Figure S5. Co-localization of CLN-5 and CD45.
Representative z-stack confocal images show double staining of isolated,
fixed PBLs with simultaneously applied CLN-5 (green) and CD45 (blue)
antibodies. Some steric hindrance may exist between the two antibodies, as
PBLs that bind higher CD45 antibody have a corresponding reduced CLN-5
signal. (TIF 662 kb)
Additional file 7: Figure S6. CLN-5 mRNA in PBLs. PBLs were isolated
from naïve and immunized mice at D8 and D13 post-EAE induction.
Relative CLN-5 mRNA expression values in isolated PBLs determined by
qRT-PCR are shown. mRNA values are presented as mean percent expression
relative to RPL-19 (Mean ± SEM). One-way ANOVA, followed by Tukey’s
multiple comparison post hoc analysis, was used to compare the three
groups. *p < 0.05, n = 4. (TIF 198 kb)
Additional file 8: Video 2. Aggregate formation of perivascular
eGFP-CLN-5+ leukocytes. Video of z-stack confocal image from the
spinal cord section of chimeric mouse at D9 EAE, showing an aggregate of
perivascular eGFP-CLN-5+ leukocytes (green) and their multi-nucleated
pattern with DRAQ5 (blue), adjacent to the same CNS microvessel in
Fig. 4c. (MP4 1.93 mb)
Additional file 9: Figure S7. TNF-α treatment of BMECs and CLN-5+
EV production. Total EVs were obtained by differential ultracentrifugation
from untreated control or TNF-α-treated BMECs and analyzed by Western
blotting. Only a moderate increase in the intensity of the 23-kDa CLN-5
band was observed in EVs from TNF-α-treated BMECs. BMEC cell lysate or
lysate from isolated mouse brain microvessels were used as positive
controls on the same blot. LI-COR Image Studio v5.2 was used to
perform densitometric analysis. Relative band intensities above the
background were recorded. (TIF 317 kb)
Additional file 10: Video 3. Endothelial EVs are released in vivo at sites
proximal to leukocyte adhesion. 3D surface reconstruction of an adherent
leukocyte in the lumen of an inflamed microvessel in serial EM images
from thoraco-lumbar spinal cord sections of a D13 EAE mouse. The
contour surfaces were obtained by “tracing” the leukocyte (red), EVs
(green), and endothelium (turquoise) in 130 serial sections using Imaris®,
providing a 3D view of EV-like structures, apparently aggregated, proximal
to the site of leukocyte attachment. (MP4 28 mb)
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